Results 101 to 110 of about 8,117 (271)

Contemporary Concise Review 2024: Chronic Obstructive Pulmonary Disease

Respirology, EarlyView.
SUMMARY OF KEY POINTS Non‐smoking COPD is common in LMICs, especially in women. Biomass fuel and air pollution are major risk factors with distinct pathophysiology. The ‘eosinophilic’ endotype in COPD is biologically distinct from asthma. PRISm, FEV1/FVC Z‐scores, and quantitative CT improve early COPD detection.
Sarita Thawanaphong, Parameswaran Nair
wiley   +1 more source

Successful treatment of eosinophilic chronic rhinosinusitis and eosinophilic otitis media using the anti-IL-5 receptor monoclonal antibody benralizumab: A case report

Respiratory Medicine Case Reports, 2020
Eosinophilic chronic rhinosinusitis (ECRS) is characterized by the presence of nasal polyps, dominant ethmoid shadows in computed tomography (CT) scans, and elevated levels of eosinophil infiltration into the nasal polyps and peripheral blood.
Hiroki Kagoshima, Ryusuke Hori, Tsuyoshi Kojima, Yusuke Okanoue, Atsushi Taguchi, Hirotaka Yamamoto, Koki Hasebe, Kazuhiko Shoji   +7 more
doaj  

The clinical profile of benralizumab in the management of severe eosinophilic asthma [PDF]

Therapeutic Advances in Respiratory Disease, 2016
Despite several therapeutic choices, 10–20% of patients with severe uncontrolled asthma do not respond to maximal best standard treatments, leading to a healthcare expenditure of up to 80% of overall costs for asthma. Today, there are new important therapeutic strategies, both pharmacological and interventional, that can result in improvement of ...
Francesco Menzella, Mirco Lusuardi, Luigi Zucchi, Carla Galeone, Nicola Facciolongo   +4 more
openaire   +4 more sources

Efficacy and safety of benralizumab in eosinophilic granulomatosis with polyangiitis: A meta‐analysis of eight studies

European Journal of Clinical Investigation
Eosinophilic granulomatous polyangiitis (EGPA) is a rare autoimmune disease characterized by multisystemic inflammation, with eosinophils playing a central role in its pathogenesis.
Federico Spataro, A. Solimando, Attilio Di Girolamo, Angelo Vacca, Roberto Ria   +4 more
semanticscholar   +1 more source

Circulating Mast Cell Progenitors Are Depleted by Benralizumab in Severe Asthma

Allergy, EarlyView.
Michael Fricker, John Harrington, Sarah A. Hiles, Peter G. Gibson   +3 more
wiley   +1 more source

Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity Profiles of a Single‐Dose JYB1904 in Healthy Chinese Participants: A Phase Ia, Randomized, Double‐Blind, Placebo‐Controlled Study

Clinical and Translational Science, Volume 18, Issue 6, June 2025.
ABSTRACT Allergic asthma, characterized by airborne allergen sensitivity and Th2 immune responses, is a common and increasing global health concern. Omalizumab, while effective, has limitations such as weight‐ and IgE‐dependent dosing regimens. JYB1904, a recombinant anti‐IgE humanized monoclonal antibody (IgG1 subtype), showed superior preclinical ...
Zhen‐Wei Shen, Ting‐Han Jin, Kai‐Qi Wu, Jie Zhao, Qi Jiang, Tong Guo, Liang Li, Xiao‐Hua Feng, Pei‐pei Liu, Gui‐Ling Chen   +9 more
wiley   +1 more source

Benralizumab for allergic asthma: a randomised, double-blind, placebo-controlled trial

European Respiratory Journal
Background Benralizumab induces rapid and near-complete depletion of eosinophils from blood and lung tissue. We investigated whether benralizumab could attenuate the allergen-induced late asthmatic response (LAR) in participants with allergic asthma ...
Gail M. Gauvreau, R. Sehmi, J. FitzGerald, Richard Leigh, D.W. Cockcroft, B. Davis, Irvin Mayers, L. Boulet, D. Al‐Sajee, B. Salter, Ruth P Cusack, Terence Ho, C. Whetstone, N. Alsaji, I. Satia, Kieran J. Killian, Patrick D. Mitchell, Iain P Magee, C. Bergeron, M. Bhutani, V. Werkström, T. Durżyński, Kathryn Shoemaker, R. Katial, M. Jison, P. Newbold, C. Mccrae, Paul M. O'Byrne   +27 more
semanticscholar   +1 more source

Unlocking Asthma Remission: Key Insights From an Expert Roundtable Discussion

Respirology, Volume 30, Issue 6, Page 466-479, June 2025.
ABSTRACT Treatment targets in severe asthma have evolved towards a remission‐focused paradigm guided by precision medicine. This novel concept requires a shift from evaluating the efficacy of therapies based on a single outcome at a single time point to an outcome that captures the complexity of asthma remission involving several domains assessed over ...
Dennis Thomas, Hayley Lewthwaite, Peter G. Gibson, Eleanor Majellano, Vanessa Clark, Michael Fricker, Yuto Hamada, Gary P. Anderson, Vibeke Backer, Philip Bardin, Richard Beasley, Jimmy Chien, Claude S. Farah, John Harrington, Erin Harvey, Mark Hew, Anne E. Holland, Christine Jenkins, Constance H. Katelaris, Gregory Katsoulotos, Kirsty Murray, Matthew Peters, Rejoy Thomas, Katrina Tonga, John W. Upham, Peter Wark, Vanessa M. McDonald   +26 more
wiley   +1 more source

Benralizumab does not impair antibody response to seasonal influenza vaccination in adolescent and young adult patients with moderate to severe asthma: results from the Phase IIIb ALIZE trial

Journal of Asthma and Allergy, 2018
Pamela L Zeitlin,1 Mila Leong,2 Jeremy Cole,3 Raburn M Mallory,4 Vivian H Shih,5 Richard F Olsson,6 Mitchell Goldman5 On behalf of the ALIZE study investigators 1Department of Pediatrics, National Jewish Health, Denver, CO, USA; 2Pediatric Pulmonary and ...
Zeitlin PL, Leong M, Cole J, Mallory RM, Shih VH, Olsson RF, Goldman M   +6 more
doaj  

Rapid Effect of Benralizumab for Hypereosinophilia in a Case of Severe Asthma with Eosinophilic Chronic Rhinosinusitis

Medicina, 2019
A 56-year-old man with severe asthma underwent bronchial thermoplasty (BT). However, his asthma exacerbated and hypereosinophilia developed 2 months later, thus necessitating oral corticosteroid (OCS) therapy.
Hiroaki Tsurumaki, Toshiyuki Matsuyama, Kazuma Ezawa, Yasuhiko Koga, Masakiyo Yatomi, Haruka Aoki-Saito, Kazuaki Chikamatsu, Takeshi Hisada   +7 more
doaj   +1 more source